Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,309,530
  • Shares Outstanding, K 53,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -175,850 K
  • EBIT $ -89 M
  • EBITDA $ -87 M
  • 60-Month Beta -3.12
  • Price/Sales 21.14
  • Price/Cash Flow N/A
  • Price/Book 4.89

Options Overview Details

View History
  • Implied Volatility 79.11% (-18.69%)
  • Historical Volatility 44.73%
  • IV Percentile 70%
  • IV Rank 21.82%
  • IV High 218.78% on 03/26/25
  • IV Low 40.13% on 08/14/25
  • Expected Move (DTE 4) 3.83 (8.90%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 3,203
  • Volume Avg (30-Day) 1,674
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 52,170
  • Open Int (30-Day) 51,879
  • Expected Range 39.18 to 46.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.53
  • Number of Estimates 6
  • High Estimate 0.70
  • Low Estimate 0.45
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +141.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.60 +5.41%
on 01/09/26
52.85 -15.02%
on 12/15/25
-7.09 (-13.63%)
since 12/12/25
3-Month
41.80 +7.44%
on 11/07/25
72.88 -38.38%
on 10/16/25
-18.85 (-29.56%)
since 10/10/25
52-Week
41.50 +8.22%
on 01/15/25
90.32 -50.28%
on 07/09/25
+1.80 (+4.18%)
since 01/10/25

Most Recent Stories

More News
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 42.69 (-0.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are...

SLNO : 42.69 (-0.72%)
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 42.69 (-0.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are...

SLNO : 42.69 (-0.72%)
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether...

SLNO : 42.69 (-0.72%)
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...

SLNO : 42.69 (-0.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised...

SLNO : 42.69 (-0.72%)
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...

SLNO : 42.69 (-0.72%)
Soleno Therapeutics Announces the Passing of Board Member William G. Harris

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 42.69 (-0.72%)
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 42.69 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 48.33
2nd Resistance Point 47.10
1st Resistance Point 45.05
Last Price 42.69
1st Support Level 41.78
2nd Support Level 40.55
3rd Support Level 38.50

See More

52-Week High 90.32
Fibonacci 61.8% 71.67
Fibonacci 50% 65.91
Fibonacci 38.2% 60.15
Last Price 42.69
52-Week Low 41.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar